Olorofim (orotomide) / Shionogi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345»
  • ||||||||||  Olorofim (orotomide) / F2G
    Review, Journal:  Review of the Novel Investigational Antifungal Olorofim. (Pubmed Central) -  Aug 6, 2020   
    Although published clinical outcome data have been limited to case reports to date, the results against invasive and refractory infections are promising. This review describes the mechanism of action of olorofim, its in vitro spectrum of activity, and what is currently known about its pharmacokinetic profile and clinical efficacy.
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment change, Trial completion date, Trial primary completion date:  A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim (clinicaltrials.gov) -  Jul 23, 2020   
    P1,  N=24, Recruiting, 
    This review describes the mechanism of action of olorofim, its in vitro spectrum of activity, and what is currently known about its pharmacokinetic profile and clinical efficacy. N=12 --> 24 | Trial completion date: Feb 2020 --> Dec 2023 | Trial primary completion date: Feb 2020 --> Jan 2023
  • ||||||||||  Review, Journal:  Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. (Pubmed Central) -  Mar 1, 2020   
    Additionally, novel first-in-class agents such as ibrexafungerp, an oral glucan synthase inhibitor with activity against various resistant fungal isolates, and olorofim, a pyrimidine synthesis inhibitor with a broad spectrum of activity and oral formulation, will be reviewed. Various other innovative antifungal agents and classes, including MGCD290, tetrazoles, and fosmanogepix, will also be examined.
  • ||||||||||  Review, Journal:  Hope on the Horizon: Novel Fungal Treatments in Development. (Pubmed Central) -  Feb 27, 2020   
    In addition, we will describe neurapheresis, a device used as adjunctive therapy for cryptococcosis. With a field full of novel treatments for fungal infections, the future looks promising.
  • ||||||||||  A web-based interactive tool to guide the identification of potential outbreak: usage data and users opinions () -  Feb 4, 2020 - Abstract #ECCMID2020ECCMID_2697;    
    We were able to build a tool for potential outbreak identification that was both usable and useful: it allowed experts to review incidence charts within few minutes and to identify tens, mainly with a high probability. Our goal in the future is to use these reviews to derive a reference standard to evaluation early outbreak detection algorithms within hospitals.
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial completion:  hAME: Absorption, Metabolism and Excretion of 14C-olorofim in Man (clinicaltrials.gov) -  Nov 13, 2019   
    P1,  N=12, Completed, 
    These results provide insights in the rapidly growing carbapenem-resistance in Acinetobacter spp. Recruiting --> Completed
  • ||||||||||  Olorofim (orotomide) / Shionogi
    Enrollment change, Trial withdrawal:  Radiolabelled IV and Oral Metabolism Study of F901318 (clinicaltrials.gov) -  Jul 25, 2019   
    P1,  N=0, Withdrawn, 
    Recruiting --> Completed N=10 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Olorofim (orotomide) / Shionogi
    Trial completion date, Trial initiation date, Trial primary completion date:  Radiolabelled IV and Oral Metabolism Study of F901318 (clinicaltrials.gov) -  Aug 1, 2018   
    P1,  N=10, Not yet recruiting, 
    Recruiting --> Completed Trial completion date: Sep 2017 --> Jul 2019 | Trial primary completion date: Sep 2017 --> Jul 2019 | Initiation date: Jun 2017 --> May 2019
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date:  Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients (clinicaltrials.gov) -  Feb 15, 2018   
    P2a,  N=0, Withdrawn, 
    Trial completion date: Sep 2017 --> Jul 2019 | Trial primary completion date: Sep 2017 --> Jul 2019 | Initiation date: Jun 2017 --> May 2019 N=10 --> 0 | Initiation date: Sep 2016 --> Apr 2017 | Not yet recruiting --> Withdrawn | Trial completion date: May 2017 --> Apr 2017 | Trial primary completion date: Mar 2017 --> Apr 2017
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects (clinicaltrials.gov) -  Feb 15, 2018   
    P1,  N=60, Recruiting, 
    N=18 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial completion date: Mar 2018 --> Apr 2018 | Initiation date: Dec 2017 --> Dec 2017 | Trial primary completion date: Mar 2018 --> Apr 2018
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial withdrawal:  Pharmacokinetics of IV Formulation (clinicaltrials.gov) -  Nov 1, 2017   
    P1,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting | Trial completion date: Mar 2018 --> Apr 2018 | Initiation date: Dec 2017 --> Dec 2017 | Trial primary completion date: Mar 2018 --> Apr 2018 Not yet recruiting --> Withdrawn
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment change, Trial withdrawal:  Drug/Drug Interactions With F901318 (clinicaltrials.gov) -  Nov 1, 2017   
    P1,  N=0, Withdrawn, 
    Not yet recruiting --> Withdrawn N=48 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Olorofim (orotomide) / F2G
    New P1 trial:  Drug/Drug Interactions With F901318 (clinicaltrials.gov) -  Mar 29, 2017   
    P1,  N=48, Not yet recruiting, 
  • ||||||||||  Olorofim (orotomide) / F2G
    New P1 trial:  Pharmacokinetics of IV Formulation (clinicaltrials.gov) -  Mar 10, 2017   
    P1,  N=8, Not yet recruiting, 
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial initiation date, Trial primary completion date:  Radiolabelled IV and Oral Metabolism Study of F901318 (clinicaltrials.gov) -  Mar 7, 2017   
    P1,  N=10, Not yet recruiting, 
    Recruiting --> Completed | N=24 --> 40 Initiation date: Nov 2016 --> Jun 2017 | Trial primary completion date: Jan 2017 --> Sep 2017
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment open, Trial primary completion date:  ORALMAD: Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (clinicaltrials.gov) -  Feb 14, 2017   
    P1,  N=24, Recruiting, 
    Initiation date: Nov 2016 --> Jun 2017 | Trial primary completion date: Jan 2017 --> Sep 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Mar 2017
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Study of Potential for Interaction of Fluconazole With F901318 (clinicaltrials.gov) -  Feb 2, 2017   
    P1,  N=20, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Mar 2017 Recruiting --> Completed | N=32 --> 20 | Initiation date: Jun 2016 --> Feb 2016 | Trial primary completion date: Sep 2016 --> Jun 2016
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial completion:  Evaluation of Immediate Release Tablet (clinicaltrials.gov) -  Nov 28, 2016   
    P1,  N=20, Completed, 
    Recruiting --> Completed | N=32 --> 20 | Initiation date: Jun 2016 --> Feb 2016 | Trial primary completion date: Sep 2016 --> Jun 2016 Recruiting --> Completed
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial completion:  F901318 Multiple Ascending Dose Study (clinicaltrials.gov) -  Sep 19, 2016   
    P1,  N=72, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial completion:  Single Ascending Oral Dose Study of F901318 (clinicaltrials.gov) -  Sep 19, 2016   
    P1,  N=46, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial primary completion date:  Single Ascending Oral Dose Study of F901318 (clinicaltrials.gov) -  Aug 9, 2016   
    P1,  N=40, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Apr 2016 --> Sep 2016
  • ||||||||||  Olorofim (orotomide) / F2G
    Trial primary completion date:  F901318 Multiple Ascending Dose Study (clinicaltrials.gov) -  Aug 9, 2016   
    P1,  N=72, Recruiting, 
    Trial primary completion date: Apr 2016 --> Sep 2016 Trial primary completion date: Feb 2016 --> Sep 2016
  • ||||||||||  Olorofim (orotomide) / F2G
    Enrollment open:  Evaluation of Immediate Release Tablet (clinicaltrials.gov) -  Jul 25, 2016   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Feb 2016 --> Sep 2016 Not yet recruiting --> Recruiting
  • ||||||||||  Olorofim (orotomide) / F2G
    New P1 trial:  Evaluation of Immediate Release Tablet (clinicaltrials.gov) -  Jun 22, 2016   
    P1,  N=20, Not yet recruiting,